Elizabeth Swisher MD of the University Of Washington discusses ovarian cancer focus for 2016 to include genetic analysis and target therapies at SGO 2016.
Author: admin
Elizabeth Swisher MD of the University Of Washington discusses how genomic analysis will strengthen prophylactic surgical management in inherited genetic abnormalities at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses how genomic analysis may improve prevention, screening and management of inherited ovarian cancer at SGO 2016.
Elizabeth Swisher MD of the University Of Washington discusses the clinical factors for requesting a genomic analysis for at risk patients at SGO 2016
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Giuseppe Curigliano, MD, PhD, from Istituto Europeo di Oncologia, Milan, Italy, discusses treatment-induced amenorrhoea and overall survival in pre-menopausal breast cancer patients; nipple-sparing mastectomy and outcomes from a national multicentre registry; and pathologic prognostic factors of male breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Triple-negative breast cancer (TNBC) represents a biologically and clinically heterogeneous disease. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Martine Piccart-Gebhart, MD, PhD, from Jules Bordet Institute, Brussels, Belgium, discusses the role of chemotherapy; targeted therapies, including anti-VEGF monoclonal antibody bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors; and immunotherapy for the treatment of patients with TNBC. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Fatima Cardoso, MD, from the Champalimaud Clinical Center, Lisbon, Portugal, discusses the themes of the conference, including the manifesto calling for European patients with breast cancer to be cared for in specialist breast units and the emphasis on the clinical application of new research. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, highlights recent advances in the treatment of patients with head and neck cancer, including the increasing interest in immunotherapy with the programmed death (PD-1) inhibitors, pembrolizumab and nivolumab. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses the efficacy and safety of immunotherapy for patients with non-small cell lung cancer. Promising agents include the anti-PD1 antibodies, nivolumab and pembrolizumab; the anti-PD-L1 antibodies, atezolizumab, durvalumab and avelumab; and anti-CTLA-4 antibodies, ipilimumab and tremelimumab. Challenges exist with determining how these immunotherapy approaches can be integrated in clinical practice, in order to, for example, exploit their favourable toxicity profile while avoiding immune-related adverse events. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the application of next-generation sequencing for guiding cancer treatment decision-making. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany from 24 to 27 February 2016, Viktor Grünwald, MD, PhD, from Hannover Medical School, Hannover, Germany, reviews ongoing clinical trials for the treatment of patients with metastatic renal cell carcinoma, including investigations of nivolumab versus everolimus; cabozantinib versus everolimus; and lenvatinib combined with everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Reck, MD, PhD, from the LungenClinic Grosshansdorf, Grosshansdorf, Germany, discusses immunotherapy as an option for patients with non-small cell lung cancer (NSCLC) who progress after initial treatment, as well as programmed death-ligand 1 (PD-L1) expression as a predictive biomarker for the development of immunotherapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm, Sweden, discusses the clinical value of next-generation sequencing for cancer management, including the accelerating trend towards evidence-based, multigene-driven personalised cancer therapeutics. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Why are researchers and physicians so excited about combination CLL therapy? Patient Power Founder Andrew Schorr sits down with CLL experts Dr. John Gribben, Dr. Constantine Tam and Dr. William Wierda for a CLL roundtable to discuss the rationale behind treatment combinations. Note as they mention key factors such as toxicity overlap and statistical resistance. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
In this Ask the Expert segment, MPN expert Dr. Naval Daver of MD Anderson Cancer Center explains why the current pacritinib trial is on hold and shares the positive and negative learnings thus far. Dr. Daver applauds the FDA for the hold but still views pacritinib as a valuable addition to the MPN (myeloproliferative neoplasm) armamentarium. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Why are researchers and physicians so excited about combination CLL therapy? Patient Power Founder Andrew Schorr sits down with CLL experts Dr. John Gribben, Dr. Constantine Tam and Dr. William Wierda for a CLL roundtable to discuss the rationale behind treatment combinations. Note as they mention key factors such as toxicity overlap and statistical resistance. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, reviews the clinical development of new treatment options for patients with acute myeloid leukemia, including tyrosine kinase inhibitors, monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapy.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Wolfgang Hiddemann, MD, PhD, from the University of Munich, Munich, Germany, provides an overview of chemotherapy-free approaches in clinical development for the treatment of patients with indolent lymphoma. Promising approaches include the Bruton tyrosine kinase inhibitor, ibrutinib, and PI3K-delta inhibitor, idelalisib, in combinations with anti-CD20 monoclonal antibodies; Bcl-2 inhibitors; and PD-1 immune checkpoint inhibitors.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains the different therapeutic needs of younger and older patients with acute myeloid leukemia, which is recognised as a clinically heterogeneous disease.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the upcoming International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) in New York, NY, during May 2017. The themes of the iwCLL will highlight the latest advances in the management of chronic lymphocytic leukemia CLL, including the treatment of relapsed disease; optimization of treatment combinations; understanding of molecular changes in tumor cells; and clinically meaningful interactions within the tumor microenvironment.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment landscape of chronic lymphocytic leukemia, including the development of new venetoclax-based combinations with improved treatment efficacy.
Immunotherapy is personalized therapy for people with cancer–but can it outsmart CLL? Experts Drs. John Gribben, Constantine Tam,and William Wierda, along with Patient Power Founder Andrew Schorr, review immunotherapy advances and how they could impact CLL treatment.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research of personalised approaches for the treatment of patients with chronic lymphocytic leukemia.
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Tony Choueiri, MD of Dana Farber discusses CheckMate 025 phase III trial at ASCO GU 2016
Robert Dreicer, MD of the University of Virginia Health System discusses immunotherapy in non muscle invasive bladder cancer at ASCO GU 2016.
Robert Dreicer, MD of the University of Virginia Health System discusses the how soon should we expect approval of immunotherapy in urothelial cancer at ASCO GU 2016.
Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in urothelial cancer at ASCO GU 2016.
Robert Dreicer, MD of the University of Virginia Health System discusses how Atezolizumab shows very significant activity in advanced urothelial cancer at ASCO GU 2016.
Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective Phase II study of Dose-Adjusted EPOCH-R (NCT01092182), which showed that the vast majority of patients with Burkitt’s Lymphoma achieved complete remission with the DA-EPOCH-R based therapy. The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, evaluates current and emerging approaches for managing patients with multiple myeloma, including drug sequencing and a clinical trial investigating lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed patients.
Monoclonal antibodies have been recognised for their significant potential in the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Dirk Reinhardt, MD, PhD, from Essen University Hospital, Essen, Germany, reviews the role of recent advances in the understanding of the biology of acute myeloid leukemia in children for the development of new therapeutic approaches.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, discusses significant advances in the treatment of lymphoma, including approaches that decrease the toxicity and increase the efficacy of chemotherapy; and approaches that reduce the use of chemotherapy, such as monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapy.
Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Schrappe, MD, PhD, from University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, explains that there have been significant advances in the understanding of pediatric ALL subtypes and there is now a need to define the clinical importance of these subtypes.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, reviews the development of more tailored approaches for the treatment of lymphoma that have improved outcomes in patients.
Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, discusses some of the challenges posed by the rising cost of treatments.
At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, examines the recent progress in the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and myelodyplastic syndrome (MDS).
At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany, discusses the development of treatment guidelines for patients with metastatic melanoma, including the challenges and next steps of applying the results from recent clinical trials into daily practice. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
What are monoclonal antibodies, and how are they used to treat CLL? From MD Anderson Cancer Center, Drs. Zeev Estrov and Michael Keating describe the function and properties of antibodies. As Dr. Keating says, Antibodies are key elements in everything we do in CLL because eventually most patients will develop significantly low levels of the normal gamma globulins. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Are you refractory to some of the existing myeloma medications? Are you a relapsed patient? Myeloma experts Drs. John Burke, Faith Davies and Noopur Raje along with patient advocate, Jack Aiello, gathered at the 2015 American Society of Hematology (ASH) meeting for a discussion covering subjects of maintenance treatment until progression to deepen response and achieve MRD negativity, creative uses of combination therapy, and specific clinical trials, all aimed to improve relapsed and refractory patients quality and quantity of life. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower…
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses how genomics in urothelial carcinomas may play much bigger role in the future at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses inhibiting autophagy in bladder cancer at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses clinical and pathological factors that can influence outcomes in upper tract urothelial cancer at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses if treatment for prior cancer develops secondary bladder cancer at ASCO GU 2016
Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer
Marin Xavier, MD of the Scripps Health discusses the management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer